Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients

Kälsch, Julia; Bechmann, Lars P.; Kälsch, Hagen; Schlattjan, Martin; Erhard, J; Gerken, Guido; Canbay, Ali

doi:10.1155/2011/369168

Cited by 25 publications

(26 citation statements)

References 26 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic apoptosis can be detected by the M30 antibody, while overall cell death is determined by M65. As established previously by Feldstein et al [12], M30 is also a well-validated serum marker of NAFLD progression [19,20]. Before surgical intervention, M30 in the NAFLD patients was significantly raised compared with controls (99.2 + − 16.4 units/l compared with 319.8 + − 23.4 units/l, P < 0.0001).…”

Section: Surgery-induced Weight Loss Is Paralleled By Reduced Apoptossupporting

confidence: 64%

“…Likewise, in the present study, markers of cell death (M30 and M65) were significantly reduced in NAFL and NASH after surgery-induced weight loss. Indeed, reduced hepatocyte apoptosis after weight loss has been well established [19]. Since the liver contributes to a large extent to serum M30 in NAFLD, these findings suggest a reduction of fatty liver disease after BAS.…”

Section: Discussionmentioning

confidence: 69%

See 1 more Smart Citation

Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients

et al. 2013

Self Cite

View full text Add to dashboard Cite

Fetuin-A is a pro-inflammatory protein expressed by hepatocytes. Its course in morbidly obese patients with NAFLD (non-alcoholic fatty liver disease) following weight loss by BAS (bariatric surgery) has not been fully elucidated yet. In the present study, we prospectively examined the effects of weight loss on various metabolic factors at 4 weeks and 6 months after surgery. Blood and liver tissues were retrieved from 108 morbidly obese NAFLD patients before/during BAS, and 50 of these individuals met the criteria for NASH (non-alcoholic steatohepatitis). Fetuin-A expression was measured by qPCR (quantitative real-time PCR), Western blotting and immunohistochemistry. Hepatocyte apoptosis was quantified via M30 (caspase-cleaved cytokeratin-18 fragments). Plasma concentrations of adiponectin and fetuin-A were determined by ELISA. Serum-derived parameters were additionally taken at 4 weeks and 6 months post-operatively. In addition, primary human hepatocytes were treated with NEFA (non-esterified fatty acid) to investigate changes in fetuin-A. BMI (body mass index) decreased significantly from 53.0±1.1 to 36.4±1.9 kg/m2 in the NAFL group and from 53.3±1.1 to 37.6±1.2 kg/m2 in the NASH group (P<0.0001) at 6 months post-surgery. This was associated with diminishing M30 and M65 (total cytokeratin-18) levels over 6 months after surgery. Adiponectin levels increased continuously in NASH patients, whereas NAFL patients plateaued at 4 weeks post-operatively. Hepatic fetuin-A mRNA and protein expression was elevated before surgery-induced weight loss. However, plasma concentrations of fetuin-A increased signficantly in NASH patients 4 weeks post-operatively. Treatment of hepatocytes with NEFA led to up-regulation of fetuin-A expression. BAS probably has a beneficial effect on NAFLD, as indicated by reduced hepatocyte apoptosis and improved adipokine profiles. In addition, fetuin-A expression is more prominent in NASH.

show abstract

Section: Surgery-induced Weight Loss Is Paralleled By Reduced Apoptossupporting

confidence: 64%

Section: Discussionmentioning

confidence: 69%

Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…Kalsch et al 43 re-evaluated the hyaluronic acid as biomarkers for NAFLD and fibrosis in a cohort of 127 patients, and compared these results with the histological diagnosis of NAFLD.…”

Section: Article Nature Communications | Doi: 101038/ncomms4083mentioning

confidence: 99%

Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease

et al. 2014

View full text Add to dashboard Cite

Several liver disorders result from perturbations in the metabolism of hepatocytes, and their underlying mechanisms can be outlined through the use of genome-scale metabolic models (GEMs). Here we reconstruct a consensus GEM for hepatocytes, which we call iHepatocytes2322, that extends previous models by including an extensive description of lipid metabolism. We build iHepatocytes2322 using Human Metabolic Reaction 2.0 database and proteomics data in Human Protein Atlas, which experimentally validates the incorporated reactions. The reconstruction process enables improved annotation of the proteomics data using the network centric view of iHepatocytes2322. We then use iHepatocytes2322 to analyse transcriptomics data obtained from patients with non-alcoholic fatty liver disease. We show that blood concentrations of chondroitin and heparan sulphates are suitable for diagnosing non-alcoholic steatohepatitis and for the staging of non-alcoholic fatty liver disease. Furthermore, we observe serine deficiency in patients with NASH and identify PSPH, SHMT1 and BCAT1 as potential therapeutic targets for the treatment of non-alcoholic steatohepatitis.

show abstract

“…Despite similar baseline serum HA levels, the rise was significantly higher in type 2 diabetes patients (87). Serum HA levels were significantly higher in individuals with advanced fibrosis stages in a small sample of 127 morbidly obese patients (56 NASH and 71 NAFLD) (88). However, HA was unable to differentiate between F1 and F2 fibrosis in a similar cohort (89).…”

Section: Hyaluronic Acid In Autoimmune Hepatitismentioning

confidence: 91%